Efficacy of PD-1 Antibody Immunotherapy Combined with GN Regimen in Treating Recurrent and Metastatic Malignant Tumors
Objective:To investigate the efficacy of combination of programmed cell death receptor 1(PD-1)antibody immunotherapy and gemcitabine ombined with vinorelbine(GN)in the treatment of recurrent and metastatic nasopharyngeal malignant tumors.Method:A total of 60 patients with recurrent and metastatic nasopharyngeal malignant tumors were selected as the study objects from department of otolaryngology of Xianyou County General Hospital from January 2015 to January 2021,and they were randomly divided into control group and observation group,with 30 patients in each group.The control group received GN regimen treatment,while the observation group adopted PD-1 antibody immunotherapy combined with GN regimen.The short-term efficacy and treatment safety of the two groups were evaluated.The levels of angiogenesis indexes[endothelial growth factor(VEGF),insulin growth factor 1(IGF-1),matrix metalloproteinase-9(MMP-9)]and peripheral blood immune indexes[CD3+,CD4+/CD8+,natural killer cells(NK)]were compared between the two groups before treatment and after 3 months of treatment.Patients were followed up for 18 months and Kapan-Meier survival curve was drawn to calculate the survival time of patients.Result:The clinical effective rates of the two groups were 60.00%and 83.33%,respectively.And the effective rate was higher in observation group(P<0.05).After 3 months of treatment,the angiogenesis indexs were compared,and VEGF,IGF-1 and MMP-9 in observation group were lower than those of control group(P<0.05).After 3 months of treatment,the peripheral blood immune indexes were compared.The CD3+and CD4+/CD8+levels in observation group were higher while the NK level was lower compared to control group(P<0.05).The incidence rates of various adverse reactions revealed no statistical differences between groups(P>0.05).The observation group had longer survival time than that the control group(P<0.05).Conclusion:PD-1 antibody immunotherapy combined with GN regimen is effective in the treatment of recurrent and metastatic nasopharyngeal malignant tumors,which can effectively inhibit tumor angiogenesis,improve immune function,optimize short-term prognosis,and have a high safety factor.
Nasopharyngeal malignant tumorsProgrammed cell death receptor 1GemcitabineNavelbineEfficacyAngiogenesis indexes
国家科技期刊平台
NSTL
万方数据
